Table 1.
Clinical-pathologic characteristics of 23 localized neuroblastoma patients and copy number aberrations detected by array-CGH
| ID | Sex | Age (Months) | Primary Site/Recurrence | DNA Index | Stage | Histology | Survival (Months) | Outcome | Losses | Gains |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 25 | Adrenal/disseminated | 1.52 | 1 | Favorable | 146 | ANED | 1p36.22p 36.32, 3, X, Y | 8q24.3, 11p15.5, 11q24.2qter, 17q12 qter, 20p12.3, 20q11.12qter, 22 |
| 2 | F | 2 | Retroperitoneal/disseminated | 1.6 | 1 | Favorable | 130 | ANED | 1p35.2pter, 2p21qter, 3p 21.32pter, 4, 8, 10, 11, 12, 14q23.1qter, X | 1p35.1qter, 2p21pter, 3p21.32qter, 17q21.1qter, 22q13.32qter |
| 3 | M | 4 | Adrenal/disseminated | 1 | 1 | Favorable | 105 | ANED | 4, 11q13.3qter, 21q22.12qter | 11q12.1q13.3, 17q11.2qter |
| 4 | M | 6 | Adrenal/abdomen | 1 | 1 | Unfavorable | 2 | DOD | 1p34.2pter, 2p23.2, 3p25.2 pter, 16q23.2 qter | amp2p24.1p25.1, 7q34qter, 13q14.2qter, 17q11qter |
| 5 | M | 55 | Adrenal/disseminated | 1.09 | 2A | Unfavorable | 13 | DOD | 1p13.3pter | amp2p24.3p25.1, 8q24.3, 9q33.1 qter, 10q25.1qter, 11p15.5pter, 17q 21.3qter, 22q13.3 |
| 6 | F | 76 | Adrenal/disseminated | 1 | 2B | Favorable | 10 | DOD | X | 1q22qter, 6, 7, 13, 19p13.2qter, 21q21.3 |
| 7 | F | 43 | Adrenal/disseminated | 1.89 | 2B | Unfavorable | 47 | DOD | 1p31.3pter, 16p13.3pter, 17p11.2pter | 1p31.2qter, 17q21.31qter |
| 8 | M | 2 | Adrenal/abdomen | 1.67 | 2B | Favorable | 10 | DOD | 4, 21, X, Y | 6p21.2qter, 13pterq33.3, 17, 18 |
| 9 | M | 3 | Adrenal/abdomen | 1.90 | 2 | Favorable | 32 | AWED | 1p32.2pter, 14q21.1qter, 19p13 | 12q24.11qter, 17q12qter |
| 10 | M | 2 | Adrenal/N | 1.57 | 1 | Favorable | 126 | ANED | 4, X, Y | 6, 7, 9, 12, 13, 17, 21, 22 |
| 11 | M | 2 | Adrenal/N | 1.68 | 1 | Favorable | 147 | ANED | 16, 19 | 2, 5, 6, 8, 12, 13, 18 |
| 12 | F | 116 | Retroperitoneal/N | 1 | 1 | Favorable | 118 | ANED | 19p13.1qter | 7p21.1, 17q21.2qter |
| 13 | F | 2 | Adrenal/N | 2.77 | 1 | Favorable | 109 | ANED | 4, 9p24.1pter, 9q21.3qter, 11p15.4pter, 11p11.2q23, 14q11.2q24.3, 14q32.2qter, 19, X | 6, 7p21.3q21.11, 13, 17, 18 |
| 14 | M | 26 | Adrenal/N | 2.12 | 1 | Favorable | 95 | ANED | 11q14.1qter | 2p25.2, 11p15.5 pter, 11q12.1q 13.2, 17q12.1qter |
| 15 | F | 17 | Adrenal/N | 1.43 | 1 | Favorable | 76 | ANED | 3, 4, 5, 6, 9, 10, 11, 13, 16p13.3qter, 17, 19q12qter, 21q11.2q22.11, 22, Xpterq27.3 | 7, 8q24.3 |
| 16 | M | 116 | Adrenal/N | 1 | 1 | Favorable | 64 | ANED | 16q24.1qter, 22q11.22 | 8q24.3, 11p15.5, 17q25.1qter, 19p13.3pter, 20q13.3qter |
| 17 | M | 76 | Thorax/N | 1.87 | 2A | Favorable | 125 | ANED | — | 7, 13, 18 |
| 18 | M | 14 | Retroperitoneal/N | 1.55 | 2A | Favorable | 67 | ANED | 4, 9, 11, 14, 21, X | 2, 7, 12, 17 |
| 19 | F | 83 | Thorax/N | — | 2A | Unfavorable | 58 | ANED | 19p13.3, 22q 11.21-qter | 7, 9q33.3qter |
| 20 | M | 13 | Abdomen/N | 1.62 | 2B | Favorable | 100 | ANED | 4, X | 2, 6, 7, 8, 12, 13, 17, 20, 22q12.1qter |
| 21 | F | 28 | Adrenal/N | 1.63 | 2B | Favorable | 59 | ANED | 9, 21 | 13, 17 |
| 22 | M | 16 | Thorax/N | 2.32 | 2B | Favorable | 58 | ANED | 3p25pter | 6, 7, 10, 13, 17q11.2qter, 18 |
| 23 | M | 33 | Adrenal/N | 1 | 2B | Favorable | 38 | ANED | 1p21.3pter, 6p24pter, 8q12.1q13.2 | amp2p24.2p24.3, 17q21.2qter |
Abbreviations: M, male; ANED, alive no evidence of disease; F, female; DOD, dead of disease; AWED, alive with evidence of disease; N, none. The relevant copy number aberrations are shown in boldface.